New drug aims to keep aggressive bile duct cancer at bay after treatment

NCT ID NCT07260175

Recruiting now Disease control Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest Source: ClinicalTrials.gov ↗

Summary

This study is testing whether a drug called ivosidenib can help prevent cancer from returning in people with a specific type of bile duct cancer who have already had surgery and chemotherapy. The trial will involve about 40 patients who have a particular genetic mutation (IDH1) in their cancer cells. Participants will take ivosidenib daily for up to one year after completing their standard chemotherapy to see if it extends the time they remain cancer-free.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Klinikum rechts der Isar TU München
RECRUITING

München, 81675, Germany

Contact
Krankenhaus Nordwest
RECRUITING

Frankfurt, 60488, Germany

Contact
Uniklinik RWTH Aachen
RECRUITING

Aachen, 52074, Germany

Contact
Uniklinikum Jena
RECRUITING

Jena, 7747, Germany

Contact
Universitätsklinikum Bonn
RECRUITING

Bonn, 53127, Germany

Contact
Universitätsklinikum Frankfurt
RECRUITING

Frankfurt, 60590, Germany

Contact
Universitätsklinikum Mannheim
RECRUITING

Mannheim, 68167, Germany

Contact
Universitätsmedizin Göttingen
RECRUITING

Göttingen, 37099, Germany

Contact

Conditions

Explore the condition pages connected to this study.

CHOLANGIOCARCINOMA IDH MUTATION